Vigón et al. suggested that potentiation of memory-like NK cells and a γδ CD8+ T cell responses in dasatinib-treated CML patients may contribute to the observed resistance of these individuals’ PBMCs to HIV-1 infection. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.